$ATEX

Marquez Elena sold $341K of ATEX

Marquez Elena (Chief Financial Officer) sold 4,291 shares of Anterix Inc. (ATEX) at $79.50 ($0.34M total) on 2026-06-17.

Original reporting
SEC EDGAR · Marquez Elena
Published Jun 18, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATEX
Neutral
high confidence
Mentioned
$ATEX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings; it does not include any company performance, guidance, or regulatory/legal development.

02

Market read

Traders may monitor for clustering of insider activity, but this single sale is unlikely to drive a sustained repricing without corroborating fundamentals.

03

What to watch

Insider sales often reflect diversification, tax planning, or scheduled liquidity needs; without additional context (e.g., other insider buys/sales, guidance changes), directional inference is weak.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-18 for a 2026-06-17 sale

Background

This is an SEC Form 4 insider transaction disclosure for Anterix (ATEX) by CFO Marquez Elena.

Company-level read

Ticker impact

$ATEXNeutralHigh confidence
Context

CFO Marquez Elena filed a Form 4 selling 4,291 shares of Anterix (ATEX) at $79.50 on 2026-06-17.

Expected impact

Likely limited near-term impact; any effect is typically short-lived unless paired with other negative disclosures.

Evidence & confidence

The filing is an open-market sale with no 10b5-1 plan stated; however, insider sales alone are usually not a strong directional catalyst without accompanying guidance, enforcement, or material corporate events.

Market effects

Minimal—single insider transaction in a non-sector-wide context.

None indicated.

None indicated.

Counterpoint

Because the sale is by the CFO and explicitly notes no 10b5-1 plan, some traders may interpret it as a stronger signal than typical insider sales—though the article provides no rationale or follow-on actions.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider sale disclosure (ATEX).

  • Marquez Elena

    Chief Financial Officer who sold 4,291 shares on 2026-06-17.

Related articles

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2